Thalidomide Slows Cancer-Related Weight Loss
Posted on: Tuesday, 8 March 2005, 15:00 CST
TUESDAY, March 8 (HealthDay News) -- Thalidomide, long associated with birth defects, may have a good side: a small study finds the drug helps slow the weight loss and wasting of patients with advanced pancreatic cancer.
"In the future, combination of thalidomide with nutritional supplements and pharmacological agents may ultimately lead to a better clinical outcome," wrote British researchers reporting in the March issue of Gut.
Rapid weight loss is a hallmark of pancreatic cancer, which is often detected too late and has a very high mortality rate. The study included 50 terminally ill pancreatic cancer patients who'd already lost at least 10 percent of their body weight. Participants were randomly assigned to receive daily doses of either 200 milligrams of thalidomide or placebo for six months.
At one month, patients taking thalidomide had regained an average of 0.37 kilograms (0.8 pounds) of weight and had increased their arm muscle bulk by 1 centimeter. The patients taking the placebo had lost an average of 2.21 kilograms (nearly 5 pounds) and their arm muscle bulk had decreased by 4.46 centimeters.
After two months, those taking thalidomide had lost an average of 0.06 kilograms (0.13 pounds) of weight and their arm muscle bulk had decreased by 0.5 centimeters, compared with an average loss of 3.62 kilograms (8 pounds) of weight and 8.4 centimeters of arm muscle bulk among those taking the placebo.
The increases in weight were matched by increased physical capacity. There was no difference in survival times between the two groups. Thalidomide caused few side effects, the study said.
Severe wasting is the direct cause of death in 20 percent of patients with advanced cancer. Previous research found that thalidomide can help control wasting in AIDS patients and may help reduce weight loss in tuberculosis patients.
More information
The U.S. National Cancer Institute has more about pancreatic cancer.
SOURCE: BMJ Specialist Journals, news release, March 8, 2005~-GEN~~DRUG~
Source: HealthSCOUT
Related Articles
- Esperance Pharmaceuticals Announces Initiation of Clinical Studies of its Novel Membrane-disrupting Agent, EP-100, in Patients with Cancer
- Electronic Health Record Advances Patient-Centered Cancer Care
- Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
- Cancer Center to Use Wellness Professionals(TM) Ximega(TM) Omega-3 Supplement in Clinical Trial to Study Efficacy in Patients With Depression and Pancreatic Cancer
- FDA Approves FRAGMIN(R) As First Low-Molecular-Weight Heparin for Extended Treatment to Reduce the Recurrence of Blood Clots in Patients With Cancer
- Cephalon Receives FDA Approval of FENTORA(TM) (Fentanyl Buccal Tablet) for the Management of Breakthrough Pain in Patients With Cancer
- Cephalon Receives Approvable Letter for FENTORA(TM) (Fentanyl Buccal Tablet) for Management of Breakthrough Pain in Patients With Cancer
- Randomized Trial Shows Ganite(R) Effective When Compared With a Leading Bisphosphonate in Patients With Cancer-Related Hypercalcemia
- Higher placental weight ups breast cancer risk
- Birth Weight Linked to Cancer Risk
 |
 |
User Comments (0)
RSS Feeds